AUS
NZ
UK
CA
USA
IND
_10_04_2024_16_38_50_427275.jpg)
Highlights
- Titan Medical announces plans to delist from the Toronto Stock Exchange and transition to the TSX Venture Exchange, aiming for a more suitable trading platform.
- The move is part of a reverse takeover through the acquisition of Conavi Medical, leading to the company’s renaming to Conavi Medical Corp.
- The delisting from TSX is expected to occur between October 4 and October 10, 2024, with trading on TSXV beginning the next business day.
Titan Medical Inc., a company in the Healthcare sector, has announced its decision to voluntarily delist its common shares from the Toronto Stock Exchange (TSX). This decision is part of the company’s broader strategy to shift its operations to the TSX Venture Exchange (TSXV). The transition is tied to Titan's proposed acquisition of Conavi Medical Inc., a move that will lead to a reverse takeover and a significant restructuring within the organization.
The delisting from the TSX is anticipated to take place between October 4 and October 10, 2024. Titan Medical Inc (TSX: TMD)’s board of directors has indicated that maintaining a listing on the TSX no longer offers sufficient benefits to justify the associated costs. By moving to the TSX Venture Exchange, the company expects to continue trading on a more suitable platform, better aligned with its current stage of growth. The company has received conditional approval for listing on the TSXV, and trading on this exchange is expected to commence on the next business day following the TSX delisting.
As part of this major transition, Titan Medical will also be rebranded as Conavi Medical Corp. once the reverse takeover is finalized. This name change aligns with the acquisition of Conavi Medical Inc., marking a new chapter for the company as it expands its reach in the medical device and technology sector. The reverse takeover through a three-cornered amalgamation will enable the company to incorporate Conavi Medical’s assets and intellectual property into its operations, further enhancing its product offerings and market position.
Even after delisting from the TSX, Titan Medical will remain a reporting issuer in Canada. The company will continue to meet the disclosure requirements under Canadian securities laws, ensuring that it remains transparent with shareholders and regulatory bodies. Titan’s commitment to maintaining regular disclosure highlights the company's dedication to staying compliant with regulatory standards despite the shift in trading platforms.
The move to the TSX Venture Exchange represents a strategic adjustment for Titan Medical, as the company seeks to balance growth opportunities with the costs of maintaining a listing on a major stock exchange. By transitioning to the TSXV, the company aims to maintain its visibility in the market while operating in a more cost-effective manner.
Titan Medical’s shift to the TSXV and the acquisition of Conavi Medical Inc. indicate a focused effort to restructure and expand its business within the medical device sector. As the company undergoes these changes, its future direction under the new identity of Conavi Medical Corp. will be closely watched by the industry.
